A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

NCT07415954 · tracked via the Priya Life Science USA tracker

Sponsor

Novo Nordisk A/S

Phase

Phase 2

Started

2026-04-17

Last updated

2026-09-11

Condition(s) studied

Diabetes Mellitus, Type 2

Investigational drug(s) / intervention(s)

NNC0662-0419SemaglutidePlacebo

NNC0662-0419: NNC0662-0419 will be administered subcutaneously.

Semaglutide: Semaglutide will be administered subcutaneously.

Placebo: Placebo will be administered subcutaneously.

Study summary

This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion criteria * Male or female (sex at birth). * Age 18-75 years (both inclusive) at the time of signing the informed consent. * Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole \[mmol/mol\]) (both inclusive) as assessed by central laboratory at screening. * Willingness to obtain a high weight loss (greater than \[\>\] 25% of weight at baseline). Exclusion criteria * Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed. * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. * Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's Questionnaire.

Primary outcome measure(s)

Change in glycated haemoglobin (HbA1c) (week 16) — From baseline (week 0) to week 16
Measured as percentage-point (%-point).
Change in HbA1c (week 28) — From baseline (week 0) to week 28
Measured as %-point.
Change in HbA1c (week 40) — From baseline (week 0) to week 40
Measured as %-point.

Trial sites (63)

Facility	City	Region	Status
First Valley Medical Group	Lancaster	California	Recruiting
Torrance Clinical Research Institute, Inc.	Lomita	California	Recruiting
Ark Clinical Research	Long Beach	California	Recruiting
Pacific Clinical Studies	Los Alamitos	California	Recruiting
Wetlin Research Associates, Inc.	San Diego	California	Recruiting
Diablo Clinical Research, Inc.	Walnut Creek	California	Recruiting
Encore Medical Research LLC	Hollywood	Florida	Recruiting
Bioclinical Research Alliance	Miami	Florida	Recruiting
South Broward Research LLC	Miramar	Florida	Recruiting
West Orange Endocrinology	Ocoee	Florida	Not Yet Recruiting
Encore Medical Research of Weston	Weston	Florida	Recruiting
Elite Clinical Trials	Blackfoot	Idaho	Recruiting
Cedar-Crosse Research Center	Chicago	Illinois	Recruiting
Brigham & Women's Hospital	Boston	Massachusetts	Not Yet Recruiting
Headlands Research	Springfield	Missouri	Recruiting
PharmQuest	Greensboro	North Carolina	Recruiting
Piedmont Healthcare Statesville	Statesville	North Carolina	Recruiting
Providence Center for Clinical Research	Dayton	Ohio	Recruiting
CNS Healthcare	Memphis	Tennessee	Recruiting
University of Texas Southwestern Medical Center	Dallas	Texas	Recruiting
JCCT- Juno NW Houston	Houston	Texas	Recruiting
Consano Clinical Research, LLC	Shavano Park	Texas	Recruiting
Frontier Clinical Research - Kingwood	Kingwood	West Virginia	Not Yet Recruiting
Opca bolnica Karlovac	Karlovac	Croatia	Recruiting
Poliklinika SLAVONIJA OSIJEK	Osijek	Croatia	Recruiting
Opca bolnica Varazdin_Endocrinology	Varaždin	Croatia	Recruiting
Poliklinika Solmed	Zagreb	Croatia	Recruiting
Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ	Szeged	Csongrád-Csanád	Not Yet Recruiting
Debreceni Egyetem	Debrecen	Hajdú-Bihar	Not Yet Recruiting
Debreceni Egyetem	Debrecen	Hungary	Not Yet Recruiting
Akaicho Clinic_Internal medicine	Chiba-shi, Chiba	Japan	Active Not Recruiting
Naka Kinen Clinic_Internal medicine	Ibaraki	Japan	Active Not Recruiting
Soka Sugiura Internal Medicine Clinic	Soka-shi, Saitama	Japan	Active Not Recruiting
Tokyo-Eki Center-building Clinic_Internal Medicine	Tokyo	Japan	Active Not Recruiting
ToCROM Clinic_Internal Medicine	Tokyo	Japan	Active Not Recruiting
"Zdrowie Osteo-Medic" s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik	Bialystok	Podlaskie Voivodeship	Recruiting
Terpa Sp. z o.o. Sp. k.	Lublin	Poland	Not Yet Recruiting
Formed 2 Sp. z o.o.	Oświęcim	Poland	Recruiting
PANSTWOWY INSTYTUT MEDYCZNY MSWiA	Warsaw	Poland	Recruiting
Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Szyszko	Zabrze	Poland	Recruiting

+ 23 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07415954 on ClinicalTrials.gov ↗ ← All trials in the USA